Care for patients with tumors of the skin belongs to the most important objectives of dermatology, and has gained increased recognition both by medicine in general as well as by the public. Departments of dermatology face an urge to deal both with increasing numbers of patients, to provide a top quality patient care and to gain a visibility both within the medical community as well as in the public.

The establishment of the Skin Cancer Center Charité Berlin aims to deal with these different aspects. In order to increase effectiveness the Skin Cancer Center in Berlin is organized within sections: section for epithelial skin cancer, melanoma center, cutaneous lymphoma center and finally the dermatosurgical group. The aim of each section is to provide the best care both in primary diagnosis, in treatment and also follow-up of patients with skin cancer. At their first visit in our center, all patients with tumors of the skin will be channeled into the different sections with specialized dermatologists. At this first visit, it will be decided whether further diagnostic measures are needed in order to substantiate the diagnosis, or whether treatment procedures can be planned already. In particularly by putting strength on the follow up, our center is able provide data on the quality of our treatment, and also to maintain the connection to patients and their primary physicians.

The Skin Cancer Center Berlin is responsible for the development of clinical pathways for the major tumor entities of the skin, and as such is involved in a broad interdisciplinary discussion. Finally, the Skin Cancer Center Charité Berlin provides a platform to distribute communications to print media, television and radio as well as newspapers, and also serves as a partner for discussion with patient groups.

Since its foundation, the Skin Cancer Center Charité Berlin has increased the quality of patient care, the awareness of cutaneous oncology in the medical field as well as our visibility in the general population of our city and our country.